ZTS
Zoetis Inc.
Key Financials
Net Income
$2.7B
↑ 7.5%
Revenue
$9.5B
↑ 2.3%
Total Liabilities
$12.1B
↑ 28.2%
Shareholders' Equity
$3.3B
↓ 30.2%
EPS (Diluted)
$6.02
↑ 10.1%
Total Assets
$15.5B
↑ 8.6%
Cash & Equivalents
$1.6B
↑ 115.1%
Dividends/Share
$0.53
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/20/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 4 | 5/1/2026 | View on SEC |
| SCHEDULE 13G | 4/30/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| 4 | 4/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ZTS |
| Company Name | Zoetis Inc. |
| CIK | 1555280 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 973-822-7000 |